Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

GA-Hecate antiviral properties on HCV whole cycle represent a new antiviral class and open the door for the development of broad spectrum antivirals

Full text
Author(s):
Batista, Mariana Nogueira [1] ; da Silva Sanches, Paulo Ricardo [2] ; Carneiro, Bruno Moreira [1] ; Silva Braga, Ana Claudia [1] ; Fernandes Campos, Guilherme Rodrigues [1] ; Chilli, Eduardo Maffud [2] ; Rahal, Paula [1]
Total Authors: 7
Affiliation:
[1] UNESP Sao Paulo State Univ, Inst Biosci Language & Exact Sci, Sao Jose Do Rio Preto, SP - Brazil
[2] UNESP Sao Paulo State Univ, Inst Chem, Araraquara, SP - Brazil
Total Affiliations: 2
Document type: Journal article
Source: SCIENTIFIC REPORTS; v. 8, SEP 25 2018.
Web of Science Citations: 0
Abstract

In recent years, synthetic peptides have been considered promising targets for drug development that possess low side-effects, are cost-effective and are susceptible to rational design. Hecate was initially described as a potent bacterial inhibitor and subsequently as an anticancer drug with functions related to its lipid interaction property. Viruses, such as hepatitis C virus (HCV), have a lipid-dependent life cycle and could be affected by Hecate in many ways. Here, we assessed modifications on Hecate's N-terminus region and its effects on HCV and hepatotoxicity. Gallic acid-conjugated Hecate was the most efficient Hecate-derivative, presenting high potential as an antiviral and inhibiting between 50 to 99% of all major steps within the HCV infectious cycle. However, the most promising aspect was GA-Hecate's mechanism of action, which was associated with a balanced lipid interaction with the viral envelope and lipid droplets, as well as dsRNA intercalation, allowing for the possibility to affect other ssRNA viruses and those with a lipid-dependent cycle. (AU)

FAPESP's process: 17/00287-9 - ADAPTATION OF A RAT DERIVED HCV-RELATED RODENT HEPACIVIRUS TO THE MOUSE HOST
Grantee:Mariana Nogueira Batista
Support Opportunities: Scholarships abroad - Research Internship - Doctorate
FAPESP's process: 16/02174-4 - Assessment of synthetic peptides on directed Hepatitis C virus inhibition
Grantee:Mariana Nogueira Batista
Support Opportunities: Scholarships in Brazil - Doctorate
FAPESP's process: 13/07600-3 - CIBFar - Center for Innovation in Biodiversity and Drug Discovery
Grantee:Glaucius Oliva
Support Opportunities: Research Grants - Research, Innovation and Dissemination Centers - RIDC
FAPESP's process: 15/23244-8 - Development of new peptides and bioconjugates against Zika virus infection
Grantee:Paulo Ricardo da Silva Sanches
Support Opportunities: Scholarships in Brazil - Doctorate